A photograph of a box of Ozempic and its contents placed on a table in Dudley, North Tyneside, Britain, on October 31, 2023, is shown in the image. The study, conducted by researchers at Yale University, King’s College Hospital in London, and the nonprofit Doctors Without Borders, suggests that the blockbuster diabetes drug Ozempic could be produced for less than $5 a month, despite Novo Nordisk charging nearly $1,000 per month for the injection in the U.S. before insurance. This study raises concerns about the high price of the top-selling diabetes treatment and similar drugs for weight loss, which belong to a new class of treatments called GLP-1s. The demand for these medicines has increased significantly over the past year, even as more insurers exclude them from their plans due to cost, making it difficult for some patients to afford the drugs. The study also follows years of political pressure on Novo Nordisk and other drugmakers to reduce the high costs of diabetes care, particularly insulin. The article can be found at www.cnbc.com